Hughes M, Huang S, Pauling JD, et al. - Researchers herein explored patient priorities and ranking of factors affecting patient decision-making regarding treatment escalation in the management of Raynaud phenomenon (RP) secondary to systemic sclerosis (SSc). An online survey was disseminated through patient-led organizations and social media platforms to SSc patients. Evaluable responses were received from 747 people with self-reported SSc-RP with broad international representation. Following were the five highest-ranked (out of 13) factors that would prompt therapy escalation for SSc-RP: 1) inability to use the fingers properly 2) emergence of new digital ulcer (DU) on one or more fingers, 3) worsening pain or discomfort of Raynaud, 4) more severe attacks, and 5) if it may help with internal problems. Despite inadequately controlled symptoms, concerns regarding potential treatment side effects were reported by 47.1%; these individuals were more likely to accept ‘mild’ (~20-40%) vs ‘severe’ (2%) side effects. For uncontrolled Raynaud, different management strategies were welcomed by the patients; the strategies included adding new treatment in combination to existing (52.8%), drug substitution (40.9%), increasing the current dose (28.8%), or focussing on non-pharmacological approaches (29.7%).